Roy Fleischmann gives his thoughts on the phase IIb fenebrutinib findings in patients with biologic DMARD-refractory rheumatoid arthritis (1:09).
14-06-2019 | Rheumatoid arthritis | EULAR 2019 | Article
Browse topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA
Anifrolumab for the treatment of SLE
JAK inhibitor safety: Weighing up the data and understanding the risks
Rituximab and rheumatology practice in the COVID-19 era
Safety snapshot: Upadacitinib in patients with PsA
Repurposing rheumatology drugs for COVID-19
Telemedicine in rheumatology: COVID-19 and beyond
Managing PsA in resource-limited settings
Conferences